Market Closed -
Japan Exchange
02:00:00 2024-04-26 EDT
5-day change
1st Jan Change
2,610
JPY
+0.50%
+2.84%
+12.96%
Terumo : Plasma Innovation Business Seminar (PDF 3.62 MB)
June 23, 2022 at 04:05 am
Welcome to Investors' Day
June 23, 2022
Table of Contents
Executive Management Committee Introduction
Strategic Vision and Growth Strategy
Business Overview
Plasma Innovations Ecosystem
Wrap Up
Executive Management Committee
We have invested in talent to support our aspirations
Chetan Makam
Veerle d'Haenens
Delara Motlagh
Cynthia Hougum
John Tanner
Gene Stellon
Blood Center
Therapeutic
Cell Therapy
Plasma Innovations
Strategy,
Research &
Solutions
Systems
Technologies
Market Access &
Development
Innovation
Cindy Ng
Chris Williams
Bon Lopez
Rebecca Bortolotti
Rusty Spinney
Global Sales &
Global
Human Resources
General Counsel &
Chief Financial
Services
Manufacturing
Government Affairs
Officer
Recruited seasoned leaders to create market- driven innovation and unleash enterprise synergies
Promoted proven internal talent to build business ecosystems for next stage of growth
Extended our depth in Government Affairs, Market Access and Regulatory
Strategic Vision
Our Aspiration
Provide compelling and accessible innovations globally that unlock the power of blood and cells to improve patient outcomes and serve unmet medical needs
How this will be achieved
By inspiring and engaging our associates, we will optimize quality and deliver world-class solutions, earning customer loyalty and setting industry standards
GS26 Financial Aspiration
Sales : Near Double Digit Growth
Adjusted Operating Profit: Beyond 20%
Returned to Growth - Revenue and Profit
Historical Operating Performance
US$ in Millions
4.2%
4.7%
4.0%
8.8%
0.2%
0.0%
$872
$986
$1032
$1073
$944
$946
$872
Adjusted
14%
15%
18%
17%
14%
14%
FY16
FY17
FY18
FY19
FY20
FY21
FY 16-19 at actual FX rates; FY 20-21 at FY 21 Plan FX rates
Transformational Shifts
Shifted investment to growth areas
Diversified beyond equipment and blood
Built infrastructure in growth geographies
Sharpened strategic focus in services
Modernize infrastructure
Optimized manufacturing footprint
Implemented one global quality system
Adopted SFDC and Service Max globally
Continue investing ~12% of sales in R&D This is an excerpt of the original content. To continue reading it, access the original document here .
Attachments
Original Link
Original Document
Permalink
Disclaimer
Terumo Corporation published this content on 23 June 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 23 June 2022 08:04:02 UTC .
Penumbra, Inc. : The underdog in healthcare
04-11
Frontier Field Co., Ltd. announced that it has received funding from Terumo Corporation
03-17
CI
Jefferies Adjusts Terumo’s Price Target to 6,700 Yen From 5,300 Yen, Keeps at Buy
03-13
MT
Tranche Update on Terumo Corporation's Equity Buyback Plan announced on August 9, 2023.
03-11
CI
Terumo Corporation's Equity Buyback announced on August 9, 2023, has closed with 3,380,000 shares, representing 0.45% for ¥11,097.09 million.
03-07
CI
Terumo Repurchases 521 Million Yen Shares in February
03-04
MT
Terumo Corp to Undertake One-to-Two Share Split
02-08
MT
Terumo's Attributable Profit Climbs 13.8% in Fiscal Nine Months
02-07
MT
Transcript : Terumo Corporation, Q3 2024 Earnings Call, Feb 07, 2024
02-07
Terumo Corporation Reports Earnings Results for the Nine Months Ended December 31, 2023
02-07
CI
Terumo Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024
02-07
CI
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
02-07
CI
Terumo Reacquires Over 500,000 Shares in January
02-05
MT
Terumo Repurchases Shares
01-10
MT
Tranche Update on Terumo Corporation's Equity Buyback Plan announced on August 9, 2023.
01-09
CI
Jefferies Adjusts Terumo's Price Target to 5,300 Yen From 4,500 Yen, Keeps at Buy
01-04
MT
Hikaru Samejima to Assume Position as President and CEO of Terumo Corp. in April 2024
12-14
MT
Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024
12-14
CI
Terumo Corporation Announces Management Changes, Effective from April 1, 2024
12-14
CI
Terumo Repurchases 629,300 Shares in November
12-04
MT
Transcript : Terumo Corporation, Q2 2024 Earnings Call, Nov 15, 2023
11-15
Japanese Shares Continue Winning Streak on Wednesday Amid Rising Hopes on US Rate-Hike Pause
11-15
MT
Japan's Nikkei jumps 2% on strong earnings, dovish Fed bets
11-14
RE
Terumo's Fiscal H1 Attributable Profit Climbs on Strong Infusion, Catheter Product Sales; Shares Surge 10%
11-14
MT
Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
11-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).
More about the company
Last Close Price
2,610
JPY
Average target price
2,951
JPY
Spread / Average Target
+13.04%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1